Orange Lungs on top of blue background with latin american art watermarked on top. Lungs are sitting next to three green hexagons stacked in a curve around the lungs. Several smaller hexagons float out of the bottom left-hand side of the orange lungs.

Complimentary Registration Open for LALCA Schools of Thoracic Oncology

The 2021 LALCA School of Thoracic Oncology will consist of several unique, intense workshops from different disciplines including thoracic oncology, advocacy, allied health professionals, and pathology, specifically designed for young researchers in Latin America. Join us December 3-4, 2021.
Learn More
2021 Targeted Therapies of Lung Cancer

Abstract Submissions are open for the IASLC 2022 Targeted Therapies of Lung Cancer Meeting

The Scientific Program Committee for the IASLC 2022 Targeted Therapies of Lung Cancer Meeting is inviting the submission of scientific abstracts.
Learn More
Blue image with hexagons and lungs

Listen to the IASLC Official Podcast Lung Cancer Considered

Tune in for conversations with the researchers, health care professionals, patients, and advocates who are making a difference in the treatment of thoracic cancers. 
Listen Now
Complimentary Registration Open for LALCA Schools of Thoracic Oncology
Abstract Submissions are open for the IASLC 2022 Targeted Therapies of Lung Cancer Meeting
Listen to the IASLC Official Podcast Lung Cancer Considered

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

THE IASLC ATLAS OF DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC)

New Translations of the IASLC IHC Atlas are available! From IHC biochemistry basics to identifying biomarkers, this text provides a comprehensive view of diagnostic IHC in a reader-friendly format.

Access the IHC Atlas

In Focus

Two women stand wearing white coats smiling
ILCN article

Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective

Noemí Reguart
Nov 26, 2021
Read more
Lung Cancer Considered with Dr. Stephen Liu an IASLC Podcast. Virtual Tumor Board: NSCLC with Special Guests Dr. Erin Gillaspie and Dr. Shankar Siva. Lung Cancer Considered is funded in part by Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi-Sankyo, Lilly Oncoloy, and Mercj KGaA Darmstadt Germany.
Podcast

Virtual Tumor Board: NSCLC

Nov 22, 2021
Language Guide page 1

IASLC Language Guide

In line with the IASLC Equity Statement and in step with the ASCO Language of Respect, we are proud to announce the release of the IASLC Language Guide. The guide was established to instill best practices with commonly used phrases related to patient care. The IASLC will be folding the language found in the guide into all aspects of thoracic oncology education, from abstracts to faculty guidelines to podium presentations. 

Download the Language Guide

Access WCLC Content

Thank you for attending the WCLC 2021. Registration is ongoing through December 17, 2021. Visit the conference platform to access all meeting content. 

Access the Recordings

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.
Explore More

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.
Read more

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
15.609
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

View all Upcoming Events
IASLC Meeting
Dec 03 - Dec 04 2021

2021 LALCA Schools of Thoracic Oncology

IASLC Meeting
Feb 23 - Feb 26 2022

2022 Targeted Therapies of Lung Cancer Meeting

Open the Site
Joint Event
Mar 30 - Apr 02 2022

2022 European Lung Cancer Congress

JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

Explore Our Journals